Formulary Watch |

FDA Sets PDUFA Date for Dry Eye Disease Drug

If approved, reproxalap would be the first inhibitor of RASP to treat patients with dry eye disease. The FDA PDUFA date is Nov. 23, 2023.

FDA Okays Pediatric Indication for Takeda’s Takhzyro

FDA Accepts NDA for Zuranolone for Depression

Zuranolone is a rapid-acting neuroactive steroid that can take effect in 14 days to treat patients with major depressive disorder and postpartum depression. The FDA has assigned a PDUFA action date of Aug. 5, 2023.

FDA Warns Companies Claiming to Treat Monkeypox

FDA Approves Trodelvy for HR+/HER2- Breast Cancer

Trodelvy has been recommended as a preferred treatment for metastatic HR+/HER2- breast cancer by the National Comprehensive Cancer Network.

FDA Approves Tezspire in Pre-Filled Pen

Tezspire is a biologic that specifically targets the inflammation associated with asthma.

Cigna’s Evernorth Division Contributed $140 million in 2022 Revenue

Will the Biosimilar Amjevita Lower Costs?

FDA Approves Novel Therapy for CKD-Related Anemia

Subpotency Leads to Recall of 27 Lots of Tirosint-SOL

IBSA Pharma is recalling the hypothyroid medication because analyses showed lowered levels of levothyroxine in some lots.

Daiichi Sankyo Makes Available New Dosing Regimen for Turalio

Dosing has been lowered to reduce the risk of liver damage in patients taking Turalio, which is approved to treat patients with a rare tumor that affects the joints.

Hospital Drug Spending to Increase through July 2024

First Humira Biosimilar is Now Available

Mark Cuban’s Pharmacy Teams up With Cancer Health App

The collaboration between Cost Plus Drugs and OncoPower provides access to generic medications for patients with cancer integrated with OncoPower’s Pill Reminder tool.

Senators Reintroduce PBM Legislation

FDA Approves Orserdu to Treat Metastatic Breast Cancer

Elacestrant, now with the brand name Orserdu, is an oral selective estrogen receptor degrader (SERD), which works by blocking the effects of estrogen on hormone receptor-positive breast cancer cells.

FDA Approves Lilly’s BTK Inhibitor for Rare Blood Cancer

Jaypirca is the first BTK inhibitor specifically approved for patients with mantle cell lymphoma previously treated with a covalent BTK inhibitor. It has a wholesale acquisition cost of $21,000 per 30 days of therapy.

FDA Approves Keytruda for Lung Cancer After Surgery

This approval marks the fifth indication for Keytruda-based regimens in non-small cell lung cancer and the 34th indication in the United States.

IQVIA: Accumulator and Maximizer Programs are Growing

FDA Removes Evusheld’s EUA for COVID-19

AstraZeneca is developing a next-generation long-acting antibody for pre-exposure prophylaxis of COVID-19, which it plans to make available in the second half of 2023.

Flipt, Evio Partner on Pharmacy Benefit Solution for Employers

Analysis: Payers Restrict Medications for Autoimmune Diseases

Three out of four health plans scored a “C” or an “F” because of utilization management restrictions they place on medication for autoimmune conditions.

Payers and Specialty Drugs

In this video, Dea Belazi, president and chief executive officer of AscellaHealth, discusses how payers will approach specialty drugs.

Study: Heart Failure Patients Could Save with Inflation Reduction Act

AAM Report: PBMs, Health Plans Delay Adoption of Generics

Amazon Launches Subscription-Based Med Service

FDA to Hold Advisory Committee Meeting for ALS Drug

The Peripheral and Central Nervous System Drugs Advisory Committee meeting is scheduled for March 22, 2023, to review Biogen’s tofersen.

Optum Rx Launches Price Comparison Tool

FDA Approves New Drug for Type 2 Diabetes

Once-daily, oral SGLT2 inhibitor Brenzavvy has been shown to reduce blood sugar and improve glycemic control.

Specialty Pharmacy Trends to Watch in 2023